Camargo Pharmaceutical Services has conducted the first dosing for Elite Pharmaceuticals of a pivotal bioequivalence study in healthy volunteers for an undisclosed opioid abuse deterrent product. The product utilizes Elite’s proprietary pharmacological abuse deterrent technology. The study is a single-dose, open-label, partially randomized, three-way crossover study in which 52 healthy adult subjects will receive treatment in a partially randomized sequence. The primary objective of this ...